The goal of the Gonzalez Laboratory is to evaluate the role of angiogenic factors in the development of stroke and transient ischemic attack in patients with cerebrovascular disorders, including arteriovenous malformations, moyamoya disease (MMD), intracranial atherosclerosis and stroke. We also focus on the effects of encephaloduroarteriosynangiosis (EDAS) revascularization in the local cerebral microenvironment and the potential role of angiogenesis and arteriogenesis in this process.
We work in a multidisciplinary team with expert neuroscientists, neuroradiologists, neurologists and neurosurgeons to investigate the mechanism of angiogenesis and arteriogenesis in patients suffering from cerebrovascular disorders. Our research is supported by the NIH, the American Heart Association and philanthropic support, including the Oppenheimer Award and the Ruth and Raymond Stotter Endowment.
Our work has resulted in numerous published peer-reviewed papers in the treatment of cerebrovascular problems and specifically on subjects relevant to our laboratory work.
We have received two Innovation Science Research Awards and the National Translational Research Award from the American Heart Association, in recognition of the innovative approach and promise for clinical applicability of our current research problems.
Beyond those investigations in angiogenesis and cerebrovascular disorders, we have conducted clinical trials that have led to the encouraging evaluation of EDAS revascularization as an alternative treatment for adult patients with cerebral arterial steno-occlusive disorders, including moyamoya and ICAD.
The research in our lab is opening novel avenues for the management of devastating forms of stroke and cerebrovascular disorders for which there are currently no definitive, successful treatments.